Opinion|Videos|October 14, 2024
Understanding Prostate-Specific Antigen (PSA) Testing
Key Takeaways
- Prostate cancer screening is essential for early detection, especially in high-risk groups like men over 50, African Americans, and those with a family history.
- Routine screening, including PSA tests and digital rectal exams, aids in identifying cancer at an early, treatable stage.
Panelists discuss how the PSA test is conducted and interpreted, and clarify the definitions of high-risk and advanced prostate cancer types, including their implications for prognosis and subsequent treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is a PSA test and how is it performed? How do PSA levels guide next steps?
- Can you explain what high-risk and advanced prostate cancer are, eg, (non-metastatic castration-sensitive prostate cancer (nmCSPC) with BRC at high risk for metastases, castration-resistant prostate cancer (CRPC), and metastatic CSPC (mCSPC)? What is the prognosis for patients diagnosed with advanced disease?
Advertisement
Related to this article
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
Advertisement
Advertisement
Trending on CURE
1
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
2
FDA Approves Inluriyo Plus Verzenio for Certain Advanced Breast Cancers
3
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
4
A Vaccine Grown From a Patient's Own Cells for Cancer in the Spinal Fluid
5